TScan Therapeutics, Inc. - TCRX STOCK NEWS

TScan Therapeutics (Nasdaq: TCRX) has received FDA clearance for its investigational new drug (IND) application for TSC-100, targeting hematologic malignancies. The Phase 1 trial is set to begin in the first half of 2022. However, the IND for TSC-101 is on hold due to concerns about off-tumor reactivity. The company aims to evaluate TSC-100 against standard care in allogeneic hematopoietic cell transplantation patients, with preliminary results expected later in 2022. This milestone underscores TScan's focus on T-cell receptor engineered therapies for cancer treatment.

TScan Therapeutics (TCRX) announced the completion of IND submissions for its lead TCR-T candidates, TSC-100 and TSC-101, targeting leukemia relapse post-transplant. The company has ambitious plans for 2022, anticipating Phase 1 trials for these therapies in the first half, with preliminary results expected by the latter half of the year. TScan is also advancing its solid tumor programs, including targets like HPV16, and is positioned for strong growth with a cash reserve of $182.9 million expected to fund operations into 2024.

TScan Therapeutics (TCRX) announced significant advancements in its liquid tumor candidates TSC-100 and TSC-101 at the ASH Annual Meeting. These T-cell receptor therapies aim to address hematologic malignancies and prevent relapse post-hematopoietic cell transplant. The company plans to file investigational new drug applications for both therapies by the end of 2021. A Phase 1 clinical trial is expected to commence in H1 2021. TScan will host a virtual KOL event on December 15, 2021, to discuss the posters and clinical trial design.

TScan Therapeutics (Nasdaq: TCRX) announced a virtual event on December 15, 2021, featuring Dr. Yi-Bin Chen from MGH and Harvard Medical School. The session will focus on key insights from the company’s two poster presentations on lead T-cell receptor engineered therapies, TSC-100 and TSC-101, at the 63rd American Society of Hematology Annual Meeting. Attendees will gain insights into hematopoietic cell transplant and relapse prevention strategies. A live Q&A will follow the presentations, which will be archived on the company’s website.

TScan Therapeutics has completed the construction of a GMP manufacturing facility in Waltham, Massachusetts, aiming to support upcoming clinical milestones, including multiple IND filings for its TCR-engineered therapies TSC-100 and TSC-101 for liquid tumors. The 7,000 square-foot facility is operational and will provide early-stage production capacity. Additionally, TScan signed a ten-year lease for an extra 115,000 square feet to accommodate future growth. The company is expected to treat its first patient in the first half of 2022.

TScan Therapeutics, a biopharmaceutical company specializing in T-cell receptor engineered therapies for cancer, will participate in two upcoming investor conferences. These include the Jefferies London Healthcare Conference on November 18, 2021, and the Evercore ISI 4th Annual HealthCONx Conference on December 2, 2021. Webcasts of each fireside chat will be accessible for on-demand listening on the company’s website. TScan's lead therapies, TSC-100 and TSC-101, target hematologic malignancies and aim to prevent leukemia relapse.

TScan Therapeutics (TCRX) reported third-quarter 2021 financial results, highlighting progress in its TCR-T therapy pipeline. The company expects to file IND applications for lead liquid tumor therapies TSC-100 and TSC-101 by year-end. The newly launched TSC-204 solid tumor program targets MAGE-A1 and aims for IND submission in 2022. Financially, TScan recorded a net loss of $15.8 million, with cash reserves of $182.3 million projected to sustain operations into 2024. R&D expenses rose to $14.2 million from $5.8 million year-over-year.

TScan Therapeutics (Nasdaq: TCRX) announced two abstracts for its TCR-engineered therapies, TSC-100 and TSC-101, accepted for presentation at the ASH Annual Meeting from December 11-14, 2021. Targeted at preventing relapse post-hematopoietic cell transplant (HCT) in myeloid leukemia, these therapies focus on minor histocompatibility antigens HA-1 and HA-2. TScan plans to submit investigational new drug applications by year-end 2021. The company aims to begin a Phase 1/2 trial in Q1 2022, exploring safety and efficacy, with about 40% of patients potentially qualifying for these treatments.

TScan Therapeutics (Nasdaq: TCRX) has appointed Heather Savelle as Vice President of Investor Relations, bringing over 20 years of experience in corporate communications and investor relations, especially within the life sciences sector. David Southwell, CEO, emphasized the importance of her expertise as TScan approaches significant development milestones. Ms. Savelle expressed excitement in advancing the company's mission and plans to support the pipeline for TCR-T therapies TSC-100 and TSC-101, targeting FDA submissions in Q4 2021.